# A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144

> **NCT04689035** · PHASE1 · COMPLETED · sponsor: **Avilex Pharma** · enrollment: 46 (actual)

## Conditions studied

- Safety Issues
- Tolerance

## Interventions

- **DRUG:** AVLX-144
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04689035
- **Lead sponsor:** Avilex Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-27
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689035, "A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04689035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*